Drug
Vorolanib
Vorolanib is a pharmaceutical drug with 4 clinical trials. Historical success rate of 33.3%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
200%(2 trials)
Terminated
2(50%)
Phase Distribution
Ph phase_2
1
25%
Ph phase_1
3
75%
Phase Distribution
3
Early Stage
1
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
3(75.0%)
Phase 2Efficacy & side effects
1(25.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Not yet recruiting1
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
33.3%
Most Advanced
Phase 2
Trials by Phase
Phase 13 (75.0%)
Phase 21 (25.0%)
Trials by Status
terminated250%
not_yet_recruiting125%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
NCT04373369
completedphase_1
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT03583086
not_yet_recruitingphase_1
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
NCT06577961
terminatedphase_1
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
NCT03511222
Clinical Trials (4)
Showing 4 of 4 trials
NCT04373369Phase 2
Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
NCT03583086Phase 1
Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors
NCT06577961Phase 1
Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients
NCT03511222Phase 1
Vorolanib (X-82) Combined With Checkpoint Inhibitors in Patients With Solid Tumors
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4